{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.65","upperLimit":"17.28","value":"13.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"The observed length of life from entry into the study to death or the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"MLN8237, 50 mg, taken by mouth twice daily on Days 1-7. One cycle is 3 weeks long (21 days). CT or MRI imaging for response every other cycle (every 6 weeks). Treatment may continue until disease progression or adverse effects prohibit further therapy.","id":"OG000","title":"MLN8237"}],"paramType":"MEDIAN","populationDescription":"Eligible and treated patients.","reportingStatus":"POSTED","timeFrame":"From study entry to death or last contact, up to 5 years.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}